Schrödinger to Present at Truist Securities Life Sciences AI Symposium - Biotech & Tools

Rhea-AI Summary

Schrödinger (Nasdaq: SDGR) announced its participation in the Truist Securities Life Sciences AI Symposium on March 1, 2022. Karen Akinsanya, Ph.D., will join a panel discussing technology-enabled drug discovery at 10:10 a.m. ET. An on-demand workshop titled “Transforming Molecular Design of Novel Drug,” hosted by Ramy Farid, Ph.D., will also be available. Access details for the panel and workshop can be found in the investors section of Schrödinger's website. Founded in 1990, Schrödinger employs over 650 individuals and focuses on innovative drug discovery through its physics-based software platform.

NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate at the Truist Securities Life Sciences AI Symposium - Biotech & Tools.

Karen Akinsanya, Ph.D., president of R&D, Therapeutics, will participate in a panel about technology-enabled drug discovery which will take place on Tuesday, March 1, 2022, at 10:10 a.m. ET. Additionally, a workshop, “Transforming Molecular Design of Novel Drug,” hosted by Ramy Farid, Ph.D., chief executive officer, is available on demand.

The on demand workshop and live panel can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately seven days.

About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 650 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Twitter, or visit our blog, Extrapolations.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005997/en/

Jaren Irene Madden

Schrödinger, Inc.

jaren.madden@schrodinger.com

617-286-6264

Tracy Lessor

Schrödinger, Inc.

tracy.lessor@schrodinger.com

617-519-9827

Source: Schrödinger, Inc.

FAQ

When will Schrödinger participate in the Truist Securities Life Sciences AI Symposium?

Schrödinger will participate in the Truist Securities Life Sciences AI Symposium on March 1, 2022.

Who is speaking at the symposium for Schrödinger?

Karen Akinsanya, Ph.D., president of R&D, Therapeutics, will speak at the symposium.

What time is the panel discussion at the symposium?

The panel discussion will take place at 10:10 a.m. ET.

Is there a workshop at the Truist Securities Life Sciences AI Symposium?

Yes, there is an on-demand workshop titled 'Transforming Molecular Design of Novel Drug' hosted by Ramy Farid, Ph.D.

Where can I access the symposium presentations for Schrödinger?

The presentations can be accessed under 'News & Events' in the investors section of Schrödinger's website.

What is the focus of Schrödinger's software platform?

Schrödinger's software platform focuses on transforming therapeutic and materials discovery using physics-based methodologies.